MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Diagnostic procedures such as MRI scans may help predict early response to treatment in patients with breast cancer undergoing chemotherapy.

PURPOSE: This phase II trial is studying MRI in predicting early response to chemotherapy in patients with locally advanced breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Clinical Trials Unit, Scotland

Criteria

DISEASE CHARACTERISTICS:

• Newly diagnosed, histologically proven breast cancer

• Stage T2-4B, N0-3C, and M0 disease

• Locally advanced primary disease

• Underwent both x-ray mammography and breast ultrasound scanning during the current treatment episode

• Scheduled for neoadjuvant chemotherapy

PATIENT CHARACTERISTICS:

• Not pregnant or nursing

• Medically stable

• No renal failure

• No serious breast trauma within the past 3 months

• No known allergic reaction associated with previous administration of a paramagnetic contrast agent

• No known contraindication to magnetic resonance (MR) scanning

• Must pass the normal safety requirements of MR, particularly pacemakers and cardiac defibrillators

• No disability preventing MR scanning in the prone position

• No body habitus incompatible with MR system entry

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy

• No prior surgery or radiotherapy for cancer in the ipsilateral breast

• More than 4 months since prior surgery to the ipsilateral breast for benign breast disease